Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012)
Johnson & Johnson (JNJ) posted Income from Non-Controlling Interests of -$339.0 million for Q3 2012.
Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012) Analysis & Trends
Johnson & Johnson (JNJ) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$339.0 million in Q3 2012.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$339.0 million in Q3 2012, while the trailing twelve-month figure through Dec 2013 was -$339.0 million (changed N/A YoY) and the FY2012 annual result came in at -$339.0 million, changed N/A from the prior year.
- Income from Non-Controlling Interests steadied at -$339.0 million in Q3 2012 per JNJ's latest filing.
- The five-year high for Income from Non-Controlling Interests was -$339.0 million in Q3 2012, with the low at -$339.0 million in Q3 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | -339.00 Mn |